This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pharmacy benefit managers get out of US antitrust case over EpiPen

( April 5, 2022, 22:31 GMT | Official Statement) -- MLex Summary: CVS Health, Express Scripts, and other pharmacy benefit managers have been dismissed from a US antitrust case accusing them and Mylan of conspiring to ensure that Mylan could raise EpiPen prices while keeping a monopoly share of the market. US District Judge Eric C. Tostrud decided that plaintiffs were unable to allege any horizontal agreement among the PBMs or that PBMs had any market power in the alleged epinephrine auto-injector market. The claims were dismissed with prejudice.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections